Application of the ACOSOG Z0011 criteria to Chinese patients with breast cancer: a prospective study

• Main Authors: Yuan Peng, Miao Liu, Xianan Li, Fuzhong Tong, Yingming Cao, Peng Liu, Bo Zhou, Hongjun Liu, Lin Cheng, Jiajia Guo, Fei Xie, Houpu Yang, Siyuan Wang, Chaobin Wang, Yalin Chen, Shu Wang
• Format: Article
• Language: English
• Published: BMC 2021-04-01
• Series: World Journal of Surgical Oncology
• Subjects: Breast cancer; Sentinel lymph node; ACOSOG Z0011; Chinese
• Online Access: https://doi.org/10.1186/s12957-021-02242-1

Abstract Background Although the ACOSOG Z0011 study showed that axillary lymph node dissection (ALND) could be avoided in a specific population of sentinel lymph node-positive patients, it is not widely accepted by Chinese surgeons. We conducted a prospective single-arm study to confirm whether or not the results of Z0011 are applicable to Chinese patients. Methods Patients conforming to the Z0011 criteria were prospectively enrolled at the Peking University People’s Hospital Breast Center from November 2014 to June 2019. The clinicopathological features of the study group were compared with those of the Z0011 study group. Lymphedema after surgery, the incidence of local-regional recurrence, and survival were analyzed. Results One hundred forty-two patients who met the Z0011 eligibility criteria were enrolled in this study; 115 underwent sentinel lymph node biopsy (SLNB) alone. Compared with the Z0011 trial, younger patients were included (median age, 52 [26–82] years vs 54 [25–90] years; P = 0.03). For clinical T stage, tumor histology, hormone status, lymphovascular invasion, and the number of positive sentinel lymph nodes (SLNs), no statistically significant differences were observed. More patients received adjuvant chemotherapy and endocrine therapy in this study (90.85% vs 58.0% and 80.99% vs 46.6% respectively, P <0.001). A similar percentage of patients received radiotherapy, but more nodal radiotherapy procedures were carried out in our study (54.5% vs 16.9%). After a median follow-up of 29 months, only 1 patient (0.9%) had ipsilateral breast tumor recurrence, and no regional recurrence occurred. Conclusion Our study showed that it is achievable to avoid ALND in patients eligible for Z0011 in China. Trial registration ClinicalTrials.gov. Registration number NCT03606616 . Retrospectively registered on 31 July 2018.